The Washington Post (10/13, Ovalle) reports a study published in Molecular Psychiatry found the “tendency to use cannabis is associated with genes linked to impulsive behavior, obesity, schizophrenia and bipolar disorder, among other traits.” The research “explored the genetic traits of casual and frequent cannabis users in hopes of eventually identifying medications and other therapies to treat or prevent problematic marijuana use.” One gene associated with cannabis use identified by researchers “is involved in brain development and communication between neurons and has been linked to psychiatric disorders such as schizophrenia.” Meanwhile, “another gene is involved with signaling between nerve cells, particularly in the brain, and has been linked in previous studies to impulsive personality, obesity and cancer metastasis. The gene has also been associated with frequency of cannabis use, researchers said.”

Related Links:

— “The Washington Post (requires login and subscription)

Psychiatric News (10/9) reports that a “team of more than 100 international experts in schizophrenia have collaborated in developing a consensus criteria defining relapse.” The recommendations, published in the American Journal of Psychiatry, “include minimum and optimum requirements to meet the definition of relapse.” The experts “highlighted the following aspects of the criteria as most important: Use of field-tested, standardized rating instruments; baseline and prospective assessment of symptoms, including a verifiable diagnosis of schizophrenia and at least one acute exacerbation of illness in the past; a period of at least 12 weeks of relative stability with no more than moderate severity of symptoms against which a relapse can be measured;” and “symptom worsening of at least one week duration with an increase in severity measured as an absolute change (as opposed to a percentage change).”

Related Links:

— “International Schizophrenia Experts Develop Consensus Criteria for Relapse, Psychiatric News , October 9, 2025

The American Journal of Managed Care (10/9, Steinzor) reports a study found that “a self-guided smartphone app designed for individuals with intellectual disabilities (IDs) significantly reduced depressive symptoms and improved self-esteem and quality of life.” For the study, adults with IDs and depressive symptoms “were randomly assigned to either an intervention group using a self-help smartphone app or a waiting list control group. The app was based primarily on cognitive behavioral therapy techniques. Both groups continued receiving their usual care, which could include psychosocial support and general health services.” In intention-to-treat analyses, researchers observed that “participants in the intervention group experienced a greater reduction in depressive symptoms compared with the control group. The intervention group also showed significant improvements in quality of life and self-esteem, with the latter demonstrating a large effect size. Of the 99 participants enrolled, 92 completed the postintervention assessment, and participants reported high satisfaction with the app.” The study was published in JAMA Network Open.

Related Links:

— “Smartphone App Reduces Depression in Adults With Intellectual Disabilities,”Pearl Steinzor, The American Journal of Managed Care , October 9, 2025

MedPage Today (10/8, Firth) reports a study found that “cannabis use increased among people with psychosis after states legalized the substance for recreational use.” Researchers observed that “in states where recreational cannabis was legalized, 30-day cannabis use increased by 9.53 percentage points among people with psychosis.” This increase “was well above the 3.3-percentage point increase in past-month cannabis use among the general population observed in a recent study. Sensitivity analyses in the current study showed no significant increase in cannabis use before cannabis retail outlets opened. Weekly use did not significantly change.” The study was published in JAMA Psychiatry.

Related Links:

— MedPage Today (requires login and subscription)

Reuters (10/8, Stempel) reports New York City on Wednesday “filed a new lawsuit accusing Facebook, Google, Snapchat, TikTok and other online platforms of fueling a mental health crisis among children by addicting them to social media.” The complaint filed in “Manhattan federal court seeks damages from Facebook and Instagram owner Meta Platforms, Google and YouTube owner Alphabet, Snapchat owner Snap and TikTok owner ByteDance. It accuses the defendants of gross negligence and causing a public nuisance.” The suit alleges the companies designed their platforms to “exploit the psychology and neurophysiology of youth,” and drive compulsive use in pursuit of profit. According to Reuters, NYC “joined other governments, school districts and individuals pursuing approximately 2,050 similar lawsuits, in nationwide litigation in the Oakland, California, federal court.”

Related Links:

— “New York City sues social media companies for allegedly addicting children,”Jonathan Stempel, Reuters, October 8, 2025

Managed Healthcare Executive (10/7, Lutton) reports, “Older adults living with HIV are prescribed opioids at a higher rate and are more likely to develop opioid use disorder when compared with the general population, according to” research. Investigators “analyzed prescription and medical records of more than 650,000 Medicare beneficiaries with Part D coverage between 2008 and 2021.” The researchers “found that more than 1 in 3 (35%) of older adults with HIV received at least one opioid prescription per year during this time, while 28% of older adults without HIV received at least one opioid prescription per year.” Meanwhile, “5% of people with HIV received overlapping opioid prescriptions for more than 7 consecutive days, while only 4% of people without HIV did.” Additionally, “people living with HIV were…more likely to receive prescriptions greater than 120 mg (3%) than people without HIV (2%).” The findings were published in The Lancet Primary Care.

Related Links:

— “Opioid Prescriptions, Addiction More Common in Older HIV Patients,”Logan Lutton, Managed Healthcare Executive, October 7, 2025

Managed Healthcare Executive (10/7, Cox) reports, “All-cause mortality rates are more than three-fold higher in patients with schizophrenia, including a three-fold increased risk of death from Type 2 diabetes and a two-fold increased risk of death from cardiovascular disease,” but research “published in JAMA Psychiatry provides strong evidence that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that is given once a week, may help control metabolic risk factors in patients who are at high risk.” Investigators “evaluated semaglutide in adults with schizophrenia and prediabetes who” had overweight or obesity “and who were prescribed second-generation antipsychotics.” The investigators “found that semaglutide significantly improved both glycemic control and body weight.” Meanwhile, “from a quality-of-life standpoint, semaglutide substantially enhanced physical quality of life.”

Related Links:

— “Semaglutide as a Dual Solution for Psychiatric and Metabolic Care,” Andrew Cox, Managed Healthcare Executive, October 7, 2025

HealthDay (10/6, Thompson) reports a study found that “girls who overeat as preschoolers are more likely to develop anxiety, impulsivity and hyperactivity when they grow into teenagers.” The researchers “followed more than 2,000 Quebec children from early childhood through age 15.” They observed “three patterns of overeating in preschoolers: 60% never overate; 14% started overeating between 2 and 4 years of age; and 26% overate starting around age 4. Girls, but not boys, who started overeating at a young age were more likely than those who weren’t overeaters to report anxiety, hyperactivity and impulsivity by age 15, results show.” The study was published in BMC Pediatrics.

Related Links:

— “Overeating A Sign Of Early Mental Health Problems Among Preschooler Girls,”Dennis Thompson, HealthDay, October 6, 2025

HealthDay (10/6, Gotkine) reports a study found that “for community-dwelling older adults, late-life traumatic brain injury (TBI) is associated with higher rates of incident dementia and health care needs.” The study included 132,113 matched pairs of community-dwelling individuals older than 65 years with and without TBI. The researchers “observed associations for late-life TBI with an increased rate of incident dementia (hazard ratios, 1.69 and 1.56 for no more than five years and greater than five years, respectively); use of publicly funded home care (HR, 1.30); and long-term care home admission (HR, 1.45). Older women from low-income neighborhoods more often had dementia compared with their male peers (29.0 versus 24.7 percent). Less home care was received by residents of smaller communities than those in larger communities (60.1 versus 64.6 percent), and they had a higher probability of admission to a long-term care home (26.3 versus 21.7 percent).” The study was published in CMAJ.

Related Links:

— “Late-Life TBI Linked to Incident Dementia, Health Care Needs,”Elana Gotkine, HealthDay, October 6, 2025

Psychiatric News (10/3) reported a study found that “women with pre-menstrual dysphoric disorder (PMDD) who received hormonal suppression with leuprolide experienced an elimination of their mood symptoms, and after the ‘add-back’ of hormones, those symptoms returned.” Researchers observed that “of the 34 PMDD responders, 13 (38%) had symptom recurrence for at least one of the four mood symptoms during both estradiol add-back and progesterone add-back. An additional seven women (21%) had symptom recurrence only during progesterone add-back, and four (12%) had symptom recurrence only during estradiol add-back. In contrast, bloating and food cravings remained elevated regardless of hormone condition, while breast pain was reported as slightly more severe during estradiol add-back.” The study was published in the American Journal of Psychiatry.

Related Links:

— “Response to Hormonal Suppression, Hormonal Add-Back Distinguishes Women With PMDD, Psychiatric News, October 3, 2025